BIOMARK TEAM SECURES HEALTH CANADA LETTER OF NO OBJECTION FOR ITS GLIOBLASTOMA CLINICAL TRIAL
![biomark team secures health canada letter of no objection for its blioblastoma clinical trial](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-team-secures-health-canada-letter-of-no-objection-for-its-blioblastoma-clinical-trial.jpg)
Vancouver, British Columbia – (August 27th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled ACETYL-AMANTADINE AS A BIOMARKER IN PATIENTS WITH GLIOBLASTOMA. The company […]
BioMark Diagnostics Inc. Receives Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name “BioMark”
![biomark receives full registered trademark from USPTO](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-receives-full-registered-trademark-from-USPTO.jpg)
Vancouver, British Columbia – (July 16, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that the Company has been granted a Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name “BioMark”. The term “BioMark” was selected by the company in reference to […]
A supramolecular indicator displacement assay for acetyl amantadine
![supramolecular indicator displacement assay for acetyl amantadine, a proxy biomarker for spermidine spermine N1-acetyltransferase SSAT activity](https://www.biomarkdiagnostics.com/wp-content/uploads/2016/11/supramolecular-indicator-displacement-assay-for-acetyl-amantadine-a-proxy-biomarker-for-spermidine-spermine-N1-acetyltransferase-SSAT-activity.jpg)
A supramolecular indicator displacement assay for acetyl amantadine, a proxy biomarker for spermidine/spermine N1-acetyltransferase (SSAT) activity Introduction Cancer is a leading cause of death worldwide.1 The number of new cancer cases is expected to increase 40% in the next 15 years in Canada due to an aging and growing population.2 Lung cancer is the most […]